Overexpression of microRNA-183 in human colorectal cancer and its clinical significance
- 1 February 2014
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 26 (2) , 229-233
Abstract
Aim MicroRNA-183 (miR-183) has been shown to play a potential oncogenic role in colon cancer. The aim of this study was to evaluate the expression of miR-183 in colorectal cancer (CRC) and its potential relevance to clinicopathological characteristics and patient survival. Materials and methods Surgical specimens of cancer tissue and adjacent normal mucosa were obtained from 94 patients with CRC. The relative expression levels of miR-183 in the cancer and the normal adjacent mucosa were measured by quantitative real-time PCR. We analyzed their correlation with clinicopathological parameters and prognostic value. Results The relative expression levels of miR-183 were significantly higher in CRC tissues than in the normal adjacent mucosa (PP=0.030), lymph node metastasis (P=0.012), and distant metastasis (P=0.049). Kaplan–Meier analysis indicated that patients with high miR-183 expression had a poor overall survival (P=0.002). Moreover, multivariate analysis showed that increased expression of miR-183 was an independent predictor of overall survival. Conclusion The increased expression of miR-183 is closely related to advanced clinical stage, lymph node and distant metastases, and poor prognosis of CRC, indicating that miR-183 may serve as a predictive biomarker for the prognosis or the aggressiveness of CRC.Keywords
This publication has 9 references indexed in Scilit:
- Clinical significance of miR-22 expression in patients with colorectal cancerMedical Oncology, 2012
- Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: A case control studyBMC Cancer, 2011
- MicroRNA miR-183 Functions as an Oncogene by Targeting the Transcription FactorEGR1and Promoting Tumor Cell MigrationCancer Research, 2010
- Dysregulated miR-183 inhibits migration in breast cancer cellsBMC Cancer, 2010
- Clinicopathological and Prognostic Value of MicroRNA-21 and MicroRNA-155 in Colorectal CancerOncology, 2010
- Biomarker update for breast, colorectal and non-small cell lung cancerDrug News & Perspectives, 2010
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal CancerJNCI: Journal of the National Cancer Institute, 2009
- Genetic prognostic and predictive markers in colorectal cancerNature Reviews Cancer, 2009
- MicroRNAsCell, 2004